Sugi Predict

Sugi Predict / Compounds / SCHEMBL281941

SCHEMBL281941

SCHEMBL281941

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GPR183 P32249 6/20 1.00
▸ NPC1L1 Q9UHC9 6/20 1.00
▸ RORC P51449 4/20 1.00
▸ RORA P35398 3/20 1.00
▸ OSBP P22059 4/20 0.80
▸ OSBP2 Q969R2 2/20 0.80
▸ USP2 O75604 2/20 0.69
▸ LMNA P02545 1/20 0.69
▸ ABCB1 P08183 1/20 0.69
▸ CYP46A1 Q9Y6A2 1/20 0.69
▸ MEN1 O00255 2/20 0.67
▸ KMT2A Q03164 2/20 0.67
▸ ALOX15 P16050 1/20 0.67
▸ GRIN1 Q05586 1/20 0.58
▸ GRIN2A Q12879 1/20 0.58
▸ NR1H3 Q13133 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15083017 1.00 GPR183 (1.00) GPR183NPC1L1RORCRORAOSBP
SCHEMBL2530829 1.00 GPR183 (1.00) GPR183NPC1L1RORCRORAOSBP
SCHEMBL532560 1.00 GPR183 (1.00) GPR183NPC1L1RORCRORAOSBP
SCHEMBL289219 1.00 GPR183 (1.00) GPR183NPC1L1RORCRORAOSBP
SCHEMBL6392982 1.00 GPR183 (1.00) GPR183NPC1L1RORCRORAOSBP
SCHEMBL281942 1.00 GPR183 (1.00) GPR183NPC1L1RORCRORAOSBP
SCHEMBL23810015 1.00 GPR183 (1.00) GPR183NPC1L1RORCRORAOSBP
SCHEMBL21617323 1.00 GPR183 (1.00) GPR183NPC1L1RORCRORAOSBP
SCHEMBL22959572 1.00 GPR183 (1.00) GPR183NPC1L1RORCRORAOSBP
SCHEMBL22959500 1.00 GPR183 (1.00) GPR183NPC1L1RORCRORAOSBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 653 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090423-A1 UNIVERSAL LNP COMPOSITIONS PRIME MEDICINE, INC (US) 2026-04-30 — — WO claimed
CN-120000614-A Composite lipid nanoparticle containing cryoprotectant and preparation method and application thereof 中国科学院化学研究所 2025-05-16 — — CN claimed
EP-3554254-B1 COMPOSITIONS AND METHODS THAT MODULATE BACTERIA IN A COMPANION ANIMAL NESTLE SA (CH) 2025-05-07 — — EP claimed
CN-119912352-A Fluoro lipid nano-particles and preparation method and application thereof 中国科学院化学研究所 2025-05-02 — — CN claimed
CN-118338907-A Lipid Nanoparticle (LNP) compositions and methods of using the same 宾夕法尼亚大学董事会 2024-07-12 — — CN claimed
EP-4380574-A2 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS Buck Institute for Research on Aging (US) 2024-06-12 — — EP claimed
WO-2024109612-A1 METHOD FOR PREPARING LIPID NANOPARTICLE FOR EFFICIENTLY DELIVERING NUCLEIC ACID DRUG AND USE THEREOF 中国科学院化学研究所 2024-05-30 — — WO claimed
CN-118059061-A Preparation method and application of lipid nanoparticle for efficiently delivering nucleic acid drug 中国科学院化学研究所 2024-05-24 — — CN claimed
CN-118045169-A Lipid-charged molecule conjugate, inhalable lipid nanoparticle, and preparation method and application thereof 中国科学院化学研究所 2024-05-17 — — CN claimed
US-20240142475-A1 COMPOSITIONS AND METHODS FOR THE DETECTION OF TUBERCULOSIS WASHINGTON UNIVERSITY 2024-05-02 — — US claimed
US-20010003782-A1 Meiosis regulating compounds NOVA NORDISK A/S (DK) 2001-06-14 — — US claimed
WO-2001015676-A2 COMPOSITIONS AND METHODS FOR MODULATING HDL CHOLESTEROL AND TRIGLYCERIDE LEVELS UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-03-08 — — WO claimed
EP-1077992-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 2001-02-28 — — EP claimed
US-6184215-B1 TOPICALLY APPLYING TO SKIN A HYDROXYCHOLESTEROL TO ACTIVATE LIVER-BASED X-ACTIVATED RECEPTOR ALPHA (LXRA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2001-02-06 — — US claimed
WO-2000049992-A2 USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-08-31 — — WO claimed
EP-1019059-A1 USE OF FXR, PPARalpha AND LXRalpha ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-07-19 — — EP claimed
WO-1999058549-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 1999-11-18 — — WO claimed
WO-1998032444-A1 USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-07-30 — — WO claimed
US-5677159-A TRUNCATED; CATALYTICALLY ACTIVE NORTHEASTERN OHIO UNIVERSITY (US) 1997-10-14 — — US claimed
EP-0648842-A2 Truncated human cholesterol 7alpha-hydroxylase, method of production and use thereof Northeastern Ohio Universities (US) 1995-04-19 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010003782-A1 Meiosis regulating compounds SREBF2, SREBF1, TRIP13 GPR183 1670/4885NPC1L1 360/4885RORC 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.